Rob Fried, CEO of Niagen Bioscience, stated, “At the heart of the Niagen Plus ecosystem are our sterile pharmaceutical-grade Niagen NR formulations for IV as well as intramuscular (IM) and ...
The efficacy of continuous antibiotic prophylaxis in preventing urinary tract infection (UTI) in infants with grade III, IV, or V vesicoureteral reflux is controversial. In this investigator-initiated ...